Highlights
A collection of news and information related to Vivus Inc. published by this site and its partners.
Displaying items 1-12 of 23
» View courant.com items only
1
2
•
Next >
-
Denner added as nominee to Vivus board by activist investor
ReutersBy Bill Berkrot May 23 (Reuters) - First Manhattan Company (FMC) added some heavyweight muscle on Thursday to its bid to shake up the board of drugmaker Vivus Inc by naming former Carl Icahn top lieutenant Alex Denner and two others to its slate of...Tags: Board of Directors, Biogen Idec Incorporated, Science and Technology, Companies and Corporations, Carl Icahn
-
ANALYSIS-A hard day to be a short-seller, one of many this year
ReutersBy Ryan Vlastelica NEW YORK, May 9 (Reuters) - Three long-time favorites of the short-selling crowd are making those investors eat crow, as Tesla, Barnes & Noble and Green Mountain Coffee are racking up big gains, making an already painful year for...Tags: Arena Pharmaceuticals, Inc., Earnings, Companies and Corporations, Services and Shopping, Groupon, Inc.
-
The day ahead in business May 8
Reports: MBA mortgage index for week ended May 4, 6:30 a.m.; Crude inventories for week ended May 4, 9:30 a.m. Local earnings: CF Industries Holdings Inc., Groupon Inc., Manitex International Inc., Middleby Corp., MYR Group Inc., Nanosphere Inc.,...
Tags: Cosi Incorporated, Steinway & Sons, Enbridge Incorporated, Activision Blizzard, Inc., Hospira, Inc.
-
U.S. RESEARCH ROUNDUP: Apple, Berkshire Hathaway, Walt Disney, AIG
ReutersMay 6 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S. companies, including Apple, Berkshire Hathaway and Walt Disney, on Monday. HIGHLIGHTS * Apple : Barclays ups target price to $525 from $465; rating...Tags: Citigroup Incorporated, Marketing, YRC Worldwide Incorporated, Cincinnati Bell Incorporated, Cubic Corporation
-
EU agency backs new Roche, Astellas, Sanofi, Vivus drugs
ReutersLONDON, April 26 (Reuters) - European regulators have recommended approval of two new cancer drugs, called Erivedge and Xtandi, from Roche and Astellas. The European Medicines Agency said on Friday its experts had also backed MAC1, a tissue-engineered...Tags: Drugs and Medicines
-
FDA approves new diet drug
CNNThe Food and Drug Administration approved a new prescription diet drug called Qsymia on Tuesday. The medication produced dramatic weight loss in clinical trials, but some are concerned over potential side effects, including increased heart rate, birth...Tags: Phentermine (drug), Health and Medical Professionals, Pharmaceuticals, Marketing, Health Treatments
-
Nuevo rival para el Viagra
Los hombres con disfunción eréctil quizás no tengan que volver a hacer planes adelantados para tener relaciones sexuales, luego de que Vivus Inc. ganara la aprobación en Estados Unidos de su producto Avanafil, que viene a competir con Viagra, de Pfizer...Tags: Pfizer Inc., Levitra (drug), Cialis (drug), Health, GlaxoSmithKline PLC
-
Obesity drugs need heart studies, U.S. advisers say
ReutersSILVER SPRING, Maryland (Reuters) - Heart safety studies should be required for new obesity drugs, U.S. drug advisers said on Thursday, possibly adding a new hurdle to the drugs' approval. An advisory panel to the U.S. Food and Drug Administration...Tags: Arena Pharmaceuticals, Inc., Meridia (drug), Companies and Corporations, Heart Attack, Stock Activities
-
|Story
-
|Story
-
Diet drug Qnexa: Don't get too carried away by new study
The diet drug Qnexa helps obese people with weight-related medical conditions to lose more weight than those who take a dummy pill and could allow some to scale back on medications for diabetes, high blood pressure or cholesterol, according to a new study...Tags: Chemical Industry, Pharmaceuticals, Apples, Physical Conditions, Science and Technology
-
FDA shoots down another weight loss drug [Updated]
![The FDA has <a title="Arena Pharmaceuticals' press release" href="http://invest.arenapharm.com/releasedetail.cfm?ReleaseID=521977" target="_blank">told the makers</a> of the proposed weight-loss drug Lorcaserin that it will not at this time approve the marketing of the medication, citing concerns about its marginal effectiveness and about cancers that occurred at higher-than-usual rates in animal studies. [<b>Updated Oct. 25, 10:35 a.m.</b> An earlier version of this article said cancers occurred at higher-than-usual-rates during clinical trials.]](http://www.latimes.com/media/thumbnails/story/2010-10/57020075-24134236-187105.JPG "The FDA has <a title=\"Arena Pharmaceuticals' press release\" href=\"http://invest.arenapharm.com/releasedetail.cfm?ReleaseID=521977\" target=\"_blank\">told the makers</a> of the proposed weight-loss drug Lorcaserin that it will not at this time approve the marketing of the medication, citing concerns about its marginal effectiveness and about cancers that occurred at higher-than-usual rates in animal studies. [<b>Updated Oct. 25, 10:35 a.m.</b> An earlier version of this article said cancers occurred at higher-than-usual-rates during clinical trials.]")
The FDA has told the makers of the proposed weight-loss drug Lorcaserin that it will not at this time approve the marketing of the medication, citing concerns about its marginal effectiveness and about cancers that occurred at higher-than-usual rates...Tags: Health and Medical Professionals, Pharmaceuticals, Los Angeles Times, Arena Pharmaceuticals, Inc., Crime, Law and Justice
May 23, 2013
|Story| Reuters
May 9, 2013
|Story| Reuters
May 8, 2013
|Story| Chicago Tribune
May 6, 2013
|Story| Reuters
Apr 26, 2013
|Story| Reuters
Jul 17, 2012
|Story| CNN
Apr 30, 2012
|Story| South Florida Sun-Sentinel
Mar 29, 2012
|Story| Reuters
Feb 23, 2012
|Story| Reuters
Feb 23, 2012
|Story| Reuters
Apr 11, 2011
|Story| Los Angeles Times
Oct 25, 2010
|Story| Los Angeles Times
Original site for Vivus Inc. topic gallery.
